Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Integra Lifesciences Holdings (IART) Tax Provisions (2016 - 2026)

Integra Lifesciences Holdings' Tax Provisions history spans 17 years, with the latest figure at $6.0 million for Q4 2025.

  • On a quarterly basis, Tax Provisions rose 93.63% to $6.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$47.0 million, a 316.43% decrease, with the full-year FY2025 number at -$47.0 million, down 316.43% from a year prior.
  • Tax Provisions hit $6.0 million in Q4 2025 for Integra Lifesciences Holdings, up from -$1.4 million in the prior quarter.
  • Over the last five years, Tax Provisions for IART hit a ceiling of $21.9 million in Q1 2021 and a floor of -$46.9 million in Q2 2025.
  • Historically, Tax Provisions has averaged $1.7 million across 5 years, with a median of $5.8 million in 2023.
  • Biggest five-year swings in Tax Provisions: soared 867.46% in 2021 and later plummeted 1584.48% in 2025.
  • Tracing IART's Tax Provisions over 5 years: stood at $6.4 million in 2021, then soared by 75.89% to $11.3 million in 2022, then fell by 19.87% to $9.0 million in 2023, then crashed by 65.58% to $3.1 million in 2024, then skyrocketed by 93.63% to $6.0 million in 2025.
  • Business Quant data shows Tax Provisions for IART at $6.0 million in Q4 2025, -$1.4 million in Q3 2025, and -$46.9 million in Q2 2025.